Dr.NateNeph said:

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

1. Waist circumference: 52" → 36" ✅ Resolved
2. Triglycerides: 230 → 100 ✅ Resolved
3. HDL: 36 → 52 ✅ Resolved
4. Blood pressure: 140/92 → 118/72 ✅ Resolved
5. Fasting glucose: 125 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

AmyNC_wife said:

Lp(a) and cardiovascular risk: a nuance that matters.

Thank you for spelling out the reasoning rather than just the conclusion. I will report back once I have actually tried it.

Dr.NateNeph said:

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

Senior perspective on cardiovascular risk: I'm 70 years old and started this journey skeptically. My internist recommended it after years of failed interventions.

12 months later: down 43 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

KarenAZ_mom said:

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Tagging this one for the weekly digest.